Søgning på udtrykket 'remdesivir' giver 43 resultater


Dokumenter [2] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [9]

Dokumenter [2]

Version 21 (31.5.22) Væsentlige ændringer i denne version: Opdateret mAb anbefaling på baggrund af pågående epidemi med Omicron BA.2. Tekst om lav tærskel for procalcitonin-måling og anti-mikrobiel behandling ved tocilizumab er fjernet. Vedrørende afisolering, se særskilt vejledning på vip.regionh.dk/VIP/Admin/GUI.nsf/Desktop.html?open&openlink=https://vip.regionh.dk/VIP/Slutbruger/Portal.nsf/Main.html?open&unid=X628E0990A178D7DEC125865D003E35B3&dbpath=/VIP/Redaktoer/130177.nsf/&windo…

DSI anbefaler fortsat remdesivir ved indlæggelsekrævende COVID-19 med behov for tilskud af ilt, hvor iltmætningen i blodet er under 94% uden ilttilskud hos ellers lungeraske og, at hvor der ved røntgen af thorax påvises infiltrat(er). Dette holdningspapir omhandler baggrunden for anbefalingen.

Nyt fra tidsskrifterne [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?
Antimicrobial Agents And Chemotherapy
16.06.2022
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Infection
14.06.2022
. Abstract. . Purpose. Remdesivir is the first line hospital treatment of the SARS-CoV-2 infection. Despite its widespread use during COVID-19 pandemic, a limited number of data, also conflicting, are available about the frequency of cardiological side-effects. Additionally, identification of patients who belong to the risk groups for cardiovascular complications of antiviral treatment is difficult. . …
Infection
14.06.2022
. Abstract. . Purpose. Remdesivir is the first line hospital treatment of the SARS-CoV-2 infection. Despite its widespread use during COVID-19 pandemic, a limited number of data, also conflicting, are available about the frequency of cardiological side-effects. Additionally, identification of patients who belong to the risk groups for cardiovascular complications of antiviral treatment is difficult. . …
Antimicrobial Agents And Chemotherapy
1.06.2022
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Infection
26.05.2022
. Abstract. . Purpose. Remdesivir is FDA-approved for treatment of patients hospitalized with COVID-19 pneumonia, but not recommended in patients with severe renal failure. This study aims to evaluate the safety of remdesivir in this patient population. . . Methods. This was a single-center, retrospective cohort study including patients ≥ 18 y…
Infection
26.05.2022
. Abstract. . Purpose. Remdesivir is FDA-approved for treatment of patients hospitalized with COVID-19 pneumonia, but not recommended in patients with severe renal failure. This study aims to evaluate the safety of remdesivir in this patient population. . . Methods. This was a single-center, retrospective cohort study including patients ≥ 18 y…
Clinical Microbiology and Infection
18.05.2022
The benefits of remdesivir in the treatment of hospitalized patients with Covid-19 remain debated with the National Institutes of Health and the World Health Organization providing contradictory recommendations for and against use.
Infection
12.05.2022
. Abstract. . Purpose. The benefits of antiviral treatment with remdesivir in hospitalized patients with COVID-19 remain controversial. Clinical analyses are needed to demonstrate which patient populations are most likely to benefit. . . Methods. In a retrospective monocentric analysis, patients with COVID-19 treated between July 1, 2020 and June 30,…
Infection
12.05.2022
. Abstract. . Purpose. The benefits of antiviral treatment with remdesivir in hospitalized patients with COVID-19 remain controversial. Clinical analyses are needed to demonstrate which patient populations are most likely to benefit. . . Methods. In a retrospective monocentric analysis, patients with COVID-19 treated between July 1, 2020 and June 30,…
Antimicrobial Agents And Chemotherapy
9.05.2022
Antimicrobial Agents and Chemotherapy, Ahead of Print.
International Journal of Infectious Diseases
6.05.2022
The effectiveness of 3-days course remdesivir to prevent severe disease in COVID-19 solid organ transplant (SOT) recipients is unknown. We wanted to study the efficacy of this therapeutic option in COVID-19 SOT recipients in preventing both hospitalisations, if outpatients, and clinical worsening due to COVID-19, if already hospitalised for other reasons.
Lancet
3.05.2022
Despite 2 years having passed since the start of the COVID-19 pandemic, there is still intense debate about the best therapeutic strategy for patients with COVID-19. Multiple randomised studies have evaluated the efficacy of different antiviral,1,2 anti-inflammatory, and antithrombotic treatments. However, results have been disparate and difficult to interpret at times due to conflicting results; some trials have reported that treatments reduce mortality and other trials, reporting on the same treatment, ha…
Lancet
3.05.2022
Remdesivir has no significant effect on patients with COVID-19 who are already being ventilated. Among other hospitalised patients, it has a small effect against death or progression to ventilation (or both).
Clinical Infectious Diseases
23.04.2022
An error appeared in the 1 December 2021 issue of the journal (Benfield et al. “Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study.” Clin Infect Dis; 73(11): 2031-2036. doi.org/10.1093/cid/ciab536). Currently the author Lars Pedersen’s name is listed as “Lars Møller Pedersen.”
Infection
15.04.2022
. Abstract. . Purpose. COVID-19 patients on anti-CD20 treatment can suffer a delayed viral clearance and worse clinical outcome. We aim to present our experience with remdesivir treatment in anti-CD20-treated patients with prolonged symptoms, a patient population for which no data from randomized controlled trials are available. . . Methods. From the…
Infection
15.04.2022
. Abstract. . Purpose. COVID-19 patients on anti-CD20 treatment can suffer a delayed viral clearance and worse clinical outcome. We aim to present our experience with remdesivir treatment in anti-CD20-treated patients with prolonged symptoms, a patient population for which no data from randomized controlled trials are available. . . Methods. From the…
Journal of Medical Virology
12.04.2022
Journal of Medical Virology, Accepted Article.
International Journal of Infectious Diseases
14.03.2022
: The aim of the study is to evaluate the impact of remdesivir on overall mortality, ICU mortality and renal functional outcome in hospitalized Covid 19 kidney transplant patients.
American Journal of Tropical Medicine and Hygiene
9.03.2022
. . Journal Name: The American Journal of Tropical Medicine and HygieneVolume: 106Issue: 3Pages: 886-890. .

Aktuelle smitsomme sygdomme [9]

Medscape Infectious Diseases
23.12.2021
The study determined the risk of hospitalization or death was 87% lower in study participants who were given remdesivir than participants who received a placebo. .
Medscape Infectious Diseases
22.09.2021
In a phase 3 trial, remdesivir was linked with an 87% reduction in COVID-19-related hospitalization or all-cause death compared with placebo.
Medscape Infectious Diseases
15.07.2021
Investigators studied VA patients with COVID-19 to determine what effect the antiviral might have on hospital stay and survival.
Medscape Infectious Diseases
11.06.2021
A causal relationship between COVID-19 treatment with remdesivir and sinus bradycardia is 'at least a reasonable possibility,' the EMA's safety committee has concluded.
ProMED
26.03.2021
COVID-19 -- Worldwide/UnknownWHO region (no. countries/territories):Total confirmed cases (new cases in last 24 hours) / Total deaths (new deaths in last 24 hours)--------------------------------------------------------------------------------Western Pacific Region (19): 1 818 355 (11 116) / 31 116 (82)European Region (61): 43 403 111 (256 686) / 944 129 (3706)South East Asia Region (10): 14 407 130 (62 949) / 216 373 (395)Eastern Mediterranean Region (22): 7 280 410 (37 424) / 155 448 (453)Region of the
Medscape Infectious Diseases
23.12.2021
The study determined the risk of hospitalization or death was 87% lower in study participants who were given remdesivir than participants who received a placebo. .
Medscape Infectious Diseases
22.09.2021
In a phase 3 trial, remdesivir was linked with an 87% reduction in COVID-19-related hospitalization or all-cause death compared with placebo.
Medscape Infectious Diseases
11.06.2021
A causal relationship between COVID-19 treatment with remdesivir and sinus bradycardia is 'at least a reasonable possibility,' the EMA's safety committee has concluded.

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2022 Dansk Selskab for Infektionsmedicin

CVR: 33634307

version: 2.11.0 ● design: Christian Philip Fischer

Side indlæst på 0,574 s

Cookies og privatliv